BCL2L2 and hepatocellular carcinoma: Compared to the control group, BCL2L2 silencing increased the sensitivity of HCC cells to Lenvatinib via apoptosis induction, whereas exogenous overexpression of BCL2L2 in LR-HCC cells decreased the levels of cleaved-Caspase 3 and PARP (Fig. 5f-h).